The UK and US have announced a landmark trade agreement that will maintain no import taxes on British medicine shipments going into the US market.
The Terms of the Deal
Under the terms of the agreement, the UK has agreed to boost expenditure on medicines through the public health system. This commitment secures that tariffs on these key products will remain at nothing for a duration of the next three years.
This agreement follows earlier statements to hike import taxes on patented drug products, with figures mentioned reaching 100%.
"This agreement between the Britain bolsters the worldwide climate for new treatments and brings long-overdue equity to American-British drug exports," a statement said.
Commercial Importance
Drugs represent one of the Britain's biggest exports to the United States, which is clearly the primary market for major UK drugmakers.
Trade data reveal that in the year leading up to September, the UK shipped drugs valued at billions to the US. This value made up nearly one-fifth of British export trade in that timeframe.
"This agreement safeguards work, boosts funding and facilitates the UK to become a global hub for life sciences," a minister stated.
Key British Pledges
The deal includes several specific changes from the British government:
- Higher Cost Ceiling: The UK will lift the cost ceiling at which it considers new medicines to be too expensive by twenty-five percent.
- Increased NHS Spending: There is a target to double overall public funding on medicines from 0.3 percent of the national economy to 0.6 percent over the following ten-year period.
- Rebate Cap: The amount pharmaceutical firms must refund to the NHS to control costs will be capped at fifteen percent. Previously, refunds topped twenty percent.
Industry Background
This agreement takes place against a protracted row between the sector and the ministers over drug pricing and NHS adoption.
This friction were heightened by arguments that US consumers were charged a premium for the same drugs than consumers in the UK and Europe.
Recently, several large manufacturing plans in the UK have been paused or cancelled, while substantial investments have been directed toward US facilities.
One official publicly accepted that the NHS must spend more on drugs, noting that its budget allocation on drugs had decreased as a percentage of its total funding over the last ten years.
